Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 2/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL5206533 | 0.93 | DGAT1 (0.31) | SLC16A3SLC16A1 | |
| Pyridine SCHEMBL6069596 | 0.80 | — | — | |
| Pyridine SCHEMBL5241809 | 0.74 | NOTUM (0.32) | SLC16A3SLC16A1 | |
| SCHEMBL12670980 | 0.72 | PLA2G4A (0.45) | NPC1KMO | |
| SCHEMBL31378467 | 0.70 | PTPN11 (0.40) | NPC1 | |
| SCHEMBL23193772 | 0.69 | BRD4 (0.39) | NPC1KMO | |
| SCHEMBL29974789 | 0.69 | BRD4 (0.39) | NPC1KMO | |
| SCHEMBL21988831 | 0.68 | HSD17B10 (0.37) | NPC1KMO | |
| SCHEMBL32687927 | 0.68 | DHODH (0.36) | NPC1KMO | |
| SCHEMBL15779031 | 0.68 | NPC1 (0.40) | NPC1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585743-B1 | 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | PFIZER (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2006-07-20 | — | — | US | disclosed |
| US-7053107-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | SLC16A3 4838/4885SLC16A1 4859/4885NPC1 3489/4885 |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | SLC16A3 4838/4885SLC16A1 4859/4885NPC1 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.